JPRN-jRCTs062190030
已完成
2 期
Randomized controlled trial of the development of new treatment for depression using neurofeedback based on neuroimaging biomarkers.
Okamoto Yasumasa0 个研究点目标入组 2 人2020年1月30日
概览
- 阶段
- 2 期
- 干预措施
- 未指定
- 疾病 / 适应症
- 未指定
- 发起方
- Okamoto Yasumasa
- 入组人数
- 2
- 状态
- 已完成
- 最后更新
- 2年前
概览
简要总结
Recruiting did not proceed and the research was discontinued.
研究者
入排标准
入选标准
- •(1\)Patients aged 20 years and over,under 80 years (outpatient or hospitalized patient).
- •(2\)Subjects are diagnosed with major depressive disorder according to DSM\-TR or DSM\-5\.
- •(3\)Currently subjects meet diagnostic criteria for major depressive episodes (according to M.I.N.I.).
- •(4\)In the latest major depressive episodes,with treatment\-resistant(HRSD score is 14 points or more with sufficient doses of antidepressants for 4 weeks or more) or with treatment low tolerance(impossible to take in adequate amount antidepressants by serious side effects).
- •(5\)Signed informed consent by oneself.
排除标准
- •(1\)Incapability to understand the purpose of the study.
- •(2\)Impossible to examine on the ground of serious illness.
- •(3\)It\`s difficult for subjects below to get an MRI.
- •\- With an implanted cardiac pacemaker.
- •\- With a brain vascular clip.
- •\- Users of a nerve electrical stimulator.
- •\- With an implanted pump in one's body.
- •\- With a piece of metal in one's body.
- •\- With tattoos (including permanent makeup etc).
- •\- Pregnancy or possibly pregnant.
结局指标
主要结局
未指定
相似试验
已完成
1 期
The development of novel treatment using transcranial magnetic stimulation for patients with mood disordersJPRN-jRCTs062180023Okamoto Yasumasa3
已完成
不适用
Randomized controlled trial of the influence on mucosal regulatory T cells and fecal butyric acid by administration of Clostridium butyricum and resistant starch for pediatric ulcerative colitislcerative colitisJPRN-UMIN000023885juntendo University
已完成
不适用
ART-PterostilbeneJPRN-jRCTs031210153Kawamura Kazuhiro
已完成
2 期
Combination therapy with immune-cell therapy and immune check point inhibitormalignant tumorJPRN-jRCTc031190100Takimoto Rishu40
已完成
2 期
Combination therapy with immune-cell therapy and immune check point inhibitormalignant tumorJPRN-jRCTc031190098Takimoto Rishu40